H Lundbeck A/S
CSE:HLUN A

Watchlist Manager
H Lundbeck A/S Logo
H Lundbeck A/S
CSE:HLUN A
Watchlist
Price: 33.15 DKK 0.61%
Market Cap: 33B DKK
Have any thoughts about
H Lundbeck A/S?
Write Note

H Lundbeck A/S
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

H Lundbeck A/S
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
H Lundbeck A/S
CSE:HLUN A
Total Liabilities & Equity
kr37.4B
CAGR 3-Years
1%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Novo Nordisk A/S
CSE:NOVO B
Total Liabilities & Equity
kr397.4B
CAGR 3-Years
32%
CAGR 5-Years
26%
CAGR 10-Years
19%
ALK-Abello A/S
CSE:ALK B
Total Liabilities & Equity
kr6.7B
CAGR 3-Years
7%
CAGR 5-Years
7%
CAGR 10-Years
N/A
S
Stenocare A/S
CSE:STENO
Total Liabilities & Equity
kr37.9m
CAGR 3-Years
-12%
CAGR 5-Years
12%
CAGR 10-Years
N/A
No Stocks Found

H Lundbeck A/S
Glance View

Market Cap
32.9B DKK
Industry
Pharmaceuticals

Founded in 1915 by Hans Lundbeck, H. Lundbeck A/S has grown from a small trading company into a notable player within the pharmaceutical industry, specializing in the treatment of brain diseases. Over the decades, the company honed its focus on neuroscience, particularly targeting mental health disorders. This specialization has allowed Lundbeck to establish a strong presence in the therapeutic areas of depression, schizophrenia, Alzheimer's, and Parkinson's diseases. The company's operations are grounded in a rigorous commitment to research and development, constantly seeking breakthroughs that can transform mental health treatment. A significant portion of its revenue is channeled back into R&D to maintain its pipeline of innovative pharmaceuticals, ensuring a future driven by new drug discoveries that align with patient needs. Lundbeck’s revenue streams primarily stem from its portfolio of prescription medicines, marketed globally across numerous countries. The company capitalizes particularly on a few blockbuster drugs, forming strategic alliances and partnerships to expand its reach and efficacy. Through a robust distribution network, Lundbeck effectively channels its products from manufacturing through to consumers, including hospitals and pharmacies. Moreover, the company benefits from strategic collaborations with other pharmaceutical giants, enhancing its footprint in competitive markets. By continually investing in cutting-edge research and leveraging strategic partnerships, Lundbeck maintains its mission of delivering effective central nervous system therapies, ensuring a sustainable growth trajectory.

HLUN A Intrinsic Value
65.73 DKK
Undervaluation 50%
Intrinsic Value
Price

See Also

What is H Lundbeck A/S's Total Liabilities & Equity?
Total Liabilities & Equity
37.4B DKK

Based on the financial report for Dec 31, 2023, H Lundbeck A/S's Total Liabilities & Equity amounts to 37.4B DKK.

What is H Lundbeck A/S's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 3Y
1%

Over the last year, the Total Liabilities & Equity growth was 0%. The average annual Total Liabilities & Equity growth rates for H Lundbeck A/S have been 1% over the past three years .

Back to Top